NumFin

HTG Molecular Diagnostics, Inc.

Sümbol: HTGMQ

PNK

0.0015

USD

Turuhind täna

  • -0.0006

    P/E suhe

  • 0.0000

    PEG suhe

  • 0.00M

    MRK Cap

  • 0.00%

    DIV tootlus

HTG Molecular Diagnostics, Inc. (HTGMQ) Finantsaruanded

Download
AastaneQuarterly
LineaarneLog
Diagrammil näete HTG Molecular Diagnostics, Inc. (HTGMQ) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist NaN M, mis on NaN % gowth. Kogu perioodi keskmine brutokasum on NaN M, mis on NaN %. Keskmine brutokasumi suhtarv on NaN %. Ettevõtte eelmise aasta tulemuse puhaskasv on NaN %, mis on võrdne NaN % % keskmiselt kogu ettevõtte ajaloo jooksul.,

AastaneQuarterly
10Y20Y30Y40Y

Bilanss

Sukeldudes HTG Molecular Diagnostics, Inc. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja . Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus NaN. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud NaN aruandlusvaluutas. Selle aspekti aastane muutus on NaN%.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012

balance-sheet.row.cash-and-short-term-investments

012.221.928.7
33
31.1
10
11.8
31.5
3.6
1.8
7.3

balance-sheet.row.short-term-investments

0012.36.3
25.4
22.7
0
4.3
28.2
0
0
0

balance-sheet.row.net-receivables

01.42.11.6
3.2
5
6.4
1.4
0.7
0.8
0.6
0.2

balance-sheet.row.inventory

00.921.5
1.3
1.3
1.2
1.5
2.2
1.5
0.7
0.1

balance-sheet.row.other-current-assets

01.11.21.1
0.6
0.6
0.4
0.4
0.4
0.1
0.2
0.2

balance-sheet.row.total-current-assets

015.727.232.9
41.4
38
17.9
15.1
34.9
6
3.3
7.8

balance-sheet.row.property-plant-equipment-net

01.62.52.2
3.4
2.4
3.3
3.3
1.9
1.4
1.1
0.6

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

0000
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-investments

0000
0
0
0
0
2.6
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

00.50.80.1
0.3
3.4
0
0
0.1
1.4
0
0

balance-sheet.row.total-non-current-assets

02.13.32.3
3.8
5.8
3.3
3.3
4.6
2.7
1.1
0.6

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

017.830.535.2
45.1
43.8
21.3
18.5
39.4
8.7
4.4
8.4

balance-sheet.row.account-payables

01.21.61.3
1.7
1.8
2.4
0.8
0.7
0.9
0.8
0.6

balance-sheet.row.short-term-debt

04.35.63.7
3.7
3.4
5.8
6.4
3.1
0.8
1
0.6

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

00.56.18.9
7.5
9.7
3
5.4
7.8
10.4
0
0.2

Deferred Revenue Non Current

0000
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

00.62.62
3.1
1.5
4.4
2.5
2.5
3
1.5
1.1

balance-sheet.row.total-non-current-liabilities

04.110.113.5
12.3
15.7
11
14
16.2
29.5
24.5
24.9

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

011.41.1
1.4
0
0
0
0
0
0
0

balance-sheet.row.total-liab

012.420.120.7
21.1
22.7
24.3
24
22.6
32.8
26.8
26.7

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
45.6
35.8
25.9

balance-sheet.row.common-stock

0000
0.1
0
0
0
0
0
0
0

balance-sheet.row.retained-earnings

0-229.9-208.3-191.2
-170.3
-151
-134.6
-115.6
-89.6
-68.2
-54.2
-42.4

balance-sheet.row.accumulated-other-comprehensive-income-loss

0000
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

0235.3218.7205.7
194.2
172.1
131.5
110
106.5
-1.5
-4.1
-1.7

balance-sheet.row.total-stockholders-equity

05.410.414.5
24
21.1
-3.1
-5.6
16.9
-24
-22.4
-18.3

balance-sheet.row.total-liabilities-and-stockholders-equity

017.830.535.2
45.1
43.8
21.3
18.5
39.4
8.7
4.4
8.4

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

05.410.414.5
24
21.1
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-
-
-
-

Total Investments

0012.36.3
25.4
22.7
0
4.3
30.8
0
0
0

balance-sheet.row.total-debt

04.811.712.6
11.3
9.7
8.8
11.8
10.8
11.2
0
0.2

balance-sheet.row.net-debt

0-7.42.1-9.8
3.6
1.2
-1.2
4.3
7.6
7.6
-1.8
-7.1

Rahavoogude aruanne

HTG Molecular Diagnostics, Inc. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab NaN nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides NaN, mis tähistab NaN erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli NaN. See on NaN nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte NaN, NaN, NaN, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid NaN, kusjuures erinevus võrreldes eelmise aastaga oli NaN. Lisaks eraldas ettevõte NaN aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui NaN, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012

cash-flows.row.net-income

0-21.6-17.1-20.9
-19.3
-16.5
-19
-26
-21.4
-14
-11.8
-12.8

cash-flows.row.depreciation-and-amortization

00.60.71.3
1.7
1.5
1.2
1.5
0.7
0.5
0.3
0.2

cash-flows.row.deferred-income-tax

01.1-1.40.7
0.2
0.2
0.4
0.8
1.2
0.6
-0.1
2.2

cash-flows.row.stock-based-compensation

00.81.41.8
1.2
1.9
1.4
1
0.4
0.2
0.1
0.1

cash-flows.row.change-in-working-capital

0-0.1-1-0.2
-0.5
0
-1.2
-0.3
-0.9
-0.7
-0.5
1.3

cash-flows.row.account-receivables

00.7-0.81.6
1.8
1.3
-5
-0.7
0
-0.3
-0.5
1.7

cash-flows.row.inventory

00.1-1.4-0.3
-0.1
-0.2
0.1
0
-0.7
-0.7
-0.6
-0.1

cash-flows.row.account-payables

0-0.50.50
-0.2
-0.2
1.2
0
-0.3
0.2
0.1
0

cash-flows.row.other-working-capital

0-0.40.7-1.5
-2.1
-1
2.5
0.4
0.1
0.2
0.4
-0.3

cash-flows.row.other-non-cash-items

00.80.90.9
0
-0.4
0.9
1.6
2
0.9
0.1
2.5

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

00-0.6-0.5
-1.1
-0.9
-1
-1.9
-1.3
-0.9
-0.8
-0.1

cash-flows.row.acquisitions-net

00.100
0
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

0-7.6-18.6-12.5
-34.6
-54
0
-3.4
-38.3
0
0
0

cash-flows.row.sales-maturities-of-investments

019.912.631.6
32.2
31.7
4.3
29.8
7.5
0
0
0

cash-flows.row.other-investing-activites

0000
0
0
0
0
0
0
0
0

cash-flows.row.net-cash-used-for-investing-activites

012.4-6.718.7
-3.5
-23.2
3.3
24.4
-32.2
-0.9
-0.8
-0.1

cash-flows.row.debt-repayment

0-7.8-0.8-3.6
0
-6
-6.5
-4.6
0
-0.8
0
0

cash-flows.row.common-stock-issued

0910.77.5
20.8
38.3
19.9
2
47.7
0
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
-4.6
0
0
0

cash-flows.row.other-financing-activites

07.40.55.1
-1.3
5.9
2.3
4.6
3.5
16.4
7.1
7.2

cash-flows.row.net-cash-used-provided-by-financing-activities

08.610.49
19.4
38.1
15.8
2
51.1
15.7
7.1
7.2

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

02.6-12.811.5
-0.8
1.7
2.5
4.2
-0.3
1.8
-5.5
-1.6

cash-flows.row.cash-at-end-of-period

012.29.622.4
10.9
11.7
10
7.5
3.3
3.6
1.8
7.3

cash-flows.row.cash-at-beginning-of-period

09.622.410.9
11.7
10
7.5
3.3
3.6
1.8
7.3
8.9

cash-flows.row.operating-cash-flow

0-18.4-16.5-16.3
-16.7
-13.2
-16.6
-22.2
-19.2
-13
-11.8
-8.7

cash-flows.row.capital-expenditure

00-0.6-0.5
-1.1
-0.9
-1
-1.9
-1.3
-0.9
-0.8
-0.1

cash-flows.row.free-cash-flow

0-18.4-17.2-16.7
-17.8
-14.1
-17.6
-24.2
-20.6
-13.9
-12.6
-8.7

Kasumiaruande rida

HTG Molecular Diagnostics, Inc. tulud muutusid võrreldes eelmise perioodiga NaN%. HTGMQ brutokasum on teatatud NaN. Ettevõtte tegevuskulud on NaN, mille muutus võrreldes eelmise aastaga on NaN%. Kulud amortisatsioonikulud on NaN, mis on NaN% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on NaN, mis on NaN% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on NaN, mis tähendab NaN% kasvu võrreldes eelmise aastaga. Tegevustulu on NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on NaN%. Eelmise aasta puhaskasum oli NaN.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012

income-statement-row.row.total-revenue

06.48.98.5
19.2
21.5
14.8
5.1
4
3.3
2.2
2.5

income-statement-row.row.cost-of-revenue

04.64.14
8.9
5.1
5
4.1
3.3
3.2
2.2
1.8

income-statement-row.row.gross-profit

01.84.84.6
10.3
16.4
9.8
1
0.7
0.1
0
0.7

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

00-10
0
0
-1.2
0.1
-0.6
0
0.2
0

income-statement-row.row.operating-expenses

022.622.624.1
29.3
32.6
27.5
25.3
19.6
13
11.9
11.2

income-statement-row.row.cost-and-expenses

027.226.728.1
38.2
37.7
32.5
29.5
22.9
16.2
14.2
13

income-statement-row.row.interest-income

00.100.3
0.6
0.7
0.1
0.1
0.1
0
0
0

income-statement-row.row.interest-expense

00.91.11
1
0.9
1.3
1.8
1.6
0.7
0.2
0.3

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

000.7-0.5
-0.3
-0.1
-1.2
0.1
-0.9
-0.4
0.4
-2

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

00-10
0
0
-1.2
0.1
-0.6
0
0.2
0

income-statement-row.row.total-operating-expenses

000.7-0.5
-0.3
-0.1
-1.2
0.1
-0.9
-0.4
0.4
-2

income-statement-row.row.interest-expense

00.91.11
1
0.9
1.3
1.8
1.6
0.7
0.2
0.3

income-statement-row.row.depreciation-and-amortization

00.60.71.3
1.7
1.5
1.2
1.5
0.7
0.5
0.3
0.2

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

0-20.8-17.8-19.6
-19
-16.2
-17.7
-24.3
-18.9
-12.8
-11.9
-10.5

income-statement-row.row.income-before-tax

0-21.6-17.1-20.9
-19.3
-16.5
-19
-26
-21.4
-14
-11.8
-12.8

income-statement-row.row.income-tax-expense

0000
0
0
0
0
0
0.7
0.4
0.3

income-statement-row.row.net-income

0-21.6-17.1-20.9
-19.3
-16.5
-19
-26
-21.4
-14
-11.8
-12.8
Sarnased aktsiad
Sind võib huvitada ka:
THYROCARE.BO
Thyrocare Technologies Limited.
605.85 INR
BSE
HTGM
HTG Molecular Diagnostics, Inc..
0.48 USD
NASDAQ
CO
Global Cord Blood Corporation.
2.9876 USD
NYSE
ANPCF
ANGLE plc.
0.16678 USD
PNK
DIUXF
Diaceutics PLC.
1.3672 USD
PNK
MYGN
Myriad Genetics, Inc..
21.6 USD
NASDAQ
CNTG
Centogene N.V..
0.71 USD
NASDAQ
DMTK
DermTech, Inc..
0.6906 USD
NASDAQ
SQIDF
SQI Diagnostics Inc..
0.0149 USD
PNK

Korduma kippuv küsimus

Mis on HTG Molecular Diagnostics, Inc. (HTGMQ) koguvara?

HTG Molecular Diagnostics, Inc. (HTGMQ) koguvara on 17777655.000.

Mis on ettevõtte aastane tulu?

Aastane tulu on N/A.

Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on 0.084.

Mis on ettevõtte vaba rahavoog?

Vaba rahavoog on -2.888.

Mis on ettevõtte puhaskasumimarginaal?

Puhaskasumimarginaal on -2.808.

Mis on ettevõtte kogutulu?

Kogutulu on -2.755.

Mis on HTG Molecular Diagnostics, Inc. (HTGMQ) puhaskasum (puhaskasum)?

Puhaskasum (netotulu) on -21594476.000.

Kui suur on ettevõtte koguvõlg?

Koguvõlg on 4833948.000.

Mis on tegevuskulude arv?

Tegevuskulud on 22623682.000.

Milline on ettevõtte rahaline näitaja?

Ettevõtte raha on 0.000.